Importer of Controlled Substances; Notice of Registration, 17967-17968 [2011-7545]
Download as PDF
<![CDATA[
17967
Federal Register / Vol. 76, No. 62 / Thursday, March 31, 2011 / Notices
By order of the Commission:
Issued: March 28, 2011.
William R. Bishop,
Hearings and Meetings Coordinator.
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
[FR Doc. 2011–7671 Filed 3–29–11; 11:15 am]
BILLING CODE 7020–02–P
JOINT BOARD FOR THE
ENROLLMENT OF ACTUARIES
Meeting of the Advisory Committee;
Meeting
Joint Board for the Enrollment
of Actuaries.
AGENCY:
Notice of Federal Advisory
Committee meeting.
ACTION:
The Executive Director of the
Joint Board for the Enrollment of
Actuaries gives notice of a closed
meeting of the Advisory Committee on
Actuarial Examinations.
SUMMARY:
The meeting will be held on
April 29, 2011, from 8:30 a.m. to 5 p.m.
DATES:
The meeting will be held at
Mercer, 4400 Comerica Bank Tower,
1717 Main Street, Dallas, TX 75201.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Patrick W. McDonough, Executive
Director of the Joint Board for the
Enrollment of Actuaries, 202–622–8225.
Notice is
hereby given that the Advisory
Committee on Actuarial Examinations
will meet at Mercer, 4400 Comerica
Bank Tower, 1717 Main Street, Dallas,
TX, on April 29, 2011, from 8:30 a.m.
to 5 p.m.
The purpose of the meeting is to
discuss topics and questions that may
be recommended for inclusion on future
Joint Board examinations in actuarial
mathematics, pension law and
methodology referred to in 29 U.S.C.
1242(a)(1)(B).
A determination has been made as
required by section 10(d) of the Federal
Advisory Committee Act, 5 U.S.C. App.,
that the subject of the meeting falls
within the exception to the open
meeting requirement set forth in Title 5
U.S.C. 552b(c)(9)(B), and that the public
interest requires that such meeting be
closed to public participation.
wwoods2 on DSK1DXX6B1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
Dated: March 25, 2011.
Patrick W. McDonough,
Executive Director, Joint Board for the
Enrollment of Actuaries.
[FR Doc. 2011–7518 Filed 3–30–11; 8:45 am]
BILLING CODE 4830–01–P
VerDate Mar<15>2010
11:23 Mar 31, 2011
Jkt 223001
the following basic classes of controlled
substances:
DEPARTMENT OF JUSTICE
By Notice dated October 8, 2010, and
published in the Federal Register on
October 20, 2010 75 FR 64744, Hospira
Inc., 1776 North Centennial Drive,
McPherson, Kansas 67460–1247, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Remifentanil (9739), a basic class of
controlled substance listed in schedule
II.
The company plans to import
Remifentanil for use in dosage form
manufacturing.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Hospira Inc. to import the basic class of
controlled substance is consistent with
the public interest, and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971, at this time. DEA
has investigated Hospira Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: March 21, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug
Raw Opium (9600) .......................
Concentrate of Poppy Straw
(9670).
Schedule
II
II
The company plans to import narcotic
raw materials for manufacturing and
further distribution to its customers.
The company is registered with DEA as
a manufacturer of several controlled
substances that are manufactured from
raw opium, poppy straw, and
concentrate of poppy straw.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Cody Laboratories, Inc. to import the
basic classes of controlled substances is
consistent with the public interest, and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Cody Laboratories, Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: March 21, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–7542 Filed 3–30–11; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2011–7537 Filed 3–30–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated October 19, 2010, and
published in the Federal Register on
October 26, 2010, 75 FR 65658, Cody
Laboratories Inc., 601 Yellowstone
Avenue, Cody, Wyoming 82414–3921,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
PO 00000
Frm 00151
Fmt 4703
Sfmt 4703
Importer of Controlled Substances;
Notice of Registration
By Notice dated November 19, 2010,
and published in the Federal Register
on December 3, 2010 75 FR 75494,
Mylan Technologies, Inc., 110 Lake
Street, Saint Albans, Vermont 05478,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
the following basic classes of controlled
substances:
E:\FR\FM\31MR1.SGM
31MR1
17968
Federal Register / Vol. 76, No. 62 / Thursday, March 31, 2011 / Notices
Drug
Schedule
Methylphenidate (1724) ................
Fentanyl (9801) ............................
II
II
The company plans to import the
listed controlled substances in finished
dosage form (FDF) from foreign sources
for analytical testing and clinical trials
in which the foreign FDF will be
compared to the company’s own
domestically-manufactured FDF. This
analysis is required to allow the
company to export domesticallymanufactured FDF to foreign markets.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Mylan Pharmaceuticals, Inc. to import
the basic classes of controlled
substances is consistent with the public
interest, and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971. DEA has investigated
Mylan Pharmaceuticals, Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: March 21, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
wwoods2 on DSK1DXX6B1PROD with NOTICES
BILLING CODE 4410–09–P
Manufacturer of Controlled
Substances; Notice of Registration
DEPARTMENT OF JUSTICE
By Notice dated November 1, 2010,
and published in the Federal Register
on November 12, 2010, 75 FR 69460, GE
Healthcare, 3350 North Ridge Avenue,
Arlington Heights, Illinois 60004–1412,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
Cocaine (9041), a basic class of
controlled substance listed in schedule
II.
Jkt 223001
[FR Doc. 2011–7544 Filed 3–30–11; 8:45 am]
Drug Enforcement Administration
BILLING CODE 4410–09–P
11:23 Mar 31, 2011
Dated: March 21, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
DEPARTMENT OF JUSTICE
[FR Doc. 2011–7545 Filed 3–30–11; 8:45 am]
VerDate Mar<15>2010
The company plans to import small
quantities of ioflupane, in the form of
three separate analogues of Cocaine, to
validate production and quality control
systems, for a reference standard, and
for producing material for a future
investigational new drug (IND)
submission.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
GE Healthcare to import the basic class
of controlled substance is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. DEA has
investigated GE Healthcare to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
By Notice dated August 2, 2010, and
published in the Federal Register on
September 1, 2010, (75 FR 53720),
Austin Pharma LLC., 811 Paloma Drive,
Suite A, Round Rock, Texas 78665–
2402, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
Schedule
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Alphamethadol (9605) ..................
Nabilone (7379) ............................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
Levo-alphacetylmethadol (9648) ..
Alfentanil (9737) ...........................
PO 00000
Frm 00152
Fmt 4703
Sfmt 4703
I
I
I
II
II
II
II
II
Drug
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
Schedule
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
In reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
intermediate. This controlled substance
will be further synthesized to bulk
manufacture a synthetic THC (7370). No
other activity for this drug code is
authorized for this registration.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Austin Pharma LLC. to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Austin Pharma LLC. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: March 21, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–7540 Filed 3–30–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated August 13, 2010, and
published in the Federal Register on
September 1, 2010, 75 FR 53719,
Cambrex Charles City, Inc., 1205 11th
Street, Charles City, Iowa 50616, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Gamma Hydroxybutyric Acid (GHB)
(2010), a basic class of controlled
substance listed in schedule I.
The company plans to manufacture
Gamma Hydroxybutyric Acid (GHB)
E:\FR\FM\31MR1.SGM
31MR1
]]>Agencies
[Federal Register Volume 76, Number 62 (Thursday, March 31, 2011)]
[Notices]
[Pages 17967-17968]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-7545]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Registration
By Notice dated November 19, 2010, and published in the Federal
Register on December 3, 2010 75 FR 75494, Mylan Technologies, Inc., 110
Lake Street, Saint Albans, Vermont 05478, made application by renewal
to the Drug Enforcement Administration (DEA) to be registered as an
importer of the following basic classes of controlled substances:
[[Page 17968]]
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Methylphenidate (1724)..................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to import the listed controlled substances in
finished dosage form (FDF) from foreign sources for analytical testing
and clinical trials in which the foreign FDF will be compared to the
company's own domestically-manufactured FDF. This analysis is required
to allow the company to export domestically-manufactured FDF to foreign
markets.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and 952(a), and determined that the
registration of Mylan Pharmaceuticals, Inc. to import the basic classes
of controlled substances is consistent with the public interest, and
with United States obligations under international treaties,
conventions, or protocols in effect on May 1, 1971. DEA has
investigated Mylan Pharmaceuticals, Inc. to ensure that the company's
registration is consistent with the public interest. The investigation
has included inspection and testing of the company's physical security
systems, verification of the company's compliance with state and local
laws, and a review of the company's background and history. Therefore,
pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR
1301.34, the above named company is granted registration as an importer
of the basic classes of controlled substances listed.
Dated: March 21, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-7545 Filed 3-30-11; 8:45 am]
BILLING CODE 4410-09-P
